News in brief: Therapeutic anticoagulation no benefit in COVID-19; Combination ibrutinib and venetoclax provides lasting remission in CLL; No sleep for patients in noisy, busy wards

Therapeutic anticoagulation offers no additional benefit in COVID-19 patients Therapeutic anticoagulation with DOACs does not improves outcomes in patients hospitalised with COVID-19, a study has found. In an open-label study, 615 patients hospitalised with COVID-19 and elevated D-dimer concentration were allocated to  therapeutic anticoagulation with rivaroxaban or enoxaparin followed by rivaroxaban to day 30, or ...

Already a member?

Login to keep reading.

© 2021 the limbic